{
  "personality": null,
  "timestamp": "2025-12-11T04:52:46.625168",
  "category": "Health",
  "news_summary": "Recent advances in health reveal groundbreaking brain-computer technology, innovative gene-driven malaria control, promising supplement-based brain cancer treatment, and enhanced breast cancer therapy through fasting.",
  "news_summary_fr": "Les progrès récents dans le domaine de la santé révèlent une technologie révolutionnaire d'ordinateur cérébral, une lutte innovante contre le paludisme basée sur les gènes, un traitement prometteur du cancer du cerveau à base de suppléments et une thérapie améliorée du cancer du sein par le jeûne.",
  "news_summary_es": "Los últimos avances en el campo de la salud revelan una revolucionaria tecnología de ordenadores cerebrales, un innovador control de la malaria basado en genes, un prometedor tratamiento del cáncer cerebral basado en suplementos y una terapia mejorada del cáncer de mama mediante el ayuno.",
  "articles": [
    {
      "title": "Scientists reveal a tiny brain chip that streams thoughts in real time",
      "summary": "BISC is an ultra-thin neural implant that creates a high-bandwidth wireless link between the brain and computers. Its tiny single-chip design packs tens of thousands of electrodes and supports advanced AI models for decoding movement, perception, and intent. Initial clinical work shows it can be inserted through a small opening in the skull and remain stable while capturing detailed neural activity. The technology could reshape treatments for epilepsy, paralysis, and blindness.",
      "content": "A new brain implant could significantly reshape how people interact with computers while offering new treatment possibilities for conditions such as epilepsy, spinal cord injury, ALS, stroke, and blindness. By creating a minimally invasive, high-throughput communication path to the brain, it has the potential to support seizure control and help restore motor, speech, and visual abilities.\n\nThe promise of this technology comes from its extremely small size paired with its ability to transmit data at very high speeds. Developed through a collaboration between Columbia University, NewYork-Presbyterian Hospital, Stanford University, and the University of Pennsylvania, the device is a brain-computer interface (BCI) built around a single silicon chip. This chip forms a wireless, high-bandwidth link between the brain and external computers. The system is known as the Biological Interface System to Cortex (BISC).\n\nA study published Dec. 8 in Nature Electronics outlines BISC's architecture, which includes the chip-based implant, a wearable \"relay station,\" and the software needed to run the platform. \"Most implantable systems are built around a canister of electronics that occupies enormous volumes of space inside the body,\" says Ken Shepard, Lau Family Professor of Electrical Engineering, professor of biomedical engineering, and professor of neurological sciences at Columbia University, who served as one of the senior authors and led the engineering work. \"Our implant is a single integrated circuit chip that is so thin that it can slide into the space between the brain and the skull, resting on the brain like a piece of wet tissue paper.\"\n\nTransforming the Cortex Into a High-Bandwidth Interface\n\nShepard worked closely with senior and co-corresponding author Andreas S. Tolias, PhD, professor at the Byers Eye Institute at Stanford University and co-founding director of the Enigma Project. Tolias's extensive experience training AI systems on large-scale neural recordings, including those collected with BISC, helped the team analyze how well the implant could decode brain activity. \"BISC turns the cortical surface into an effective portal, delivering high-bandwidth, minimally invasive read-write communication with AI and external devices,\" Tolias says. \"Its single-chip scalability paves the way for adaptive neuroprosthetics and brain-AI interfaces to treat many neuropsychiatric disorders, such as epilepsy.\"\n\nDr. Brett Youngerman, assistant professor of neurological surgery at Columbia University and neurosurgeon at NewYork-Presbyterian/Columbia University Irving Medical Center, served as the project's main clinical collaborator. \"This high-resolution, high-data-throughput device has the potential to revolutionize the management of neurological conditions from epilepsy to paralysis,\" he says. Youngerman, Shepard, and NewYork-Presbyterian/Columbia epilepsy neurologist Dr. Catherine Schevon recently secured a National Institutes of Health grant to use BISC in treating drug-resistant epilepsy. \"The key to effective brain-computer interface devices is to maximize the information flow to and from the brain, while making the device as minimally invasive in its surgical implantation as possible. BISC surpasses previous technology on both fronts,\" Youngerman adds.\n\n\"Semiconductor technology has made this possible, allowing the computing power of room-sized computers to now fit in your pocket,\" Shepard says. \"We are now doing the same for medical implantables, allowing complex electronics to exist in the body while taking up almost no space.\"\n\nNext-Generation BCI Engineering\n\nBCIs function by connecting with the electrical signals used by neurons to communicate. Current medical-grade BCIs typically rely on multiple separate microelectronic components, such as amplifiers, data converters, and radio transmitters. These parts must be stored in a relatively large implanted canister, placed either by removing part of the skull or in another part of the body like the chest, with wires extending to the brain.\n\nBISC is built differently. The entire system resides on a single complementary metal-oxide-semiconductor (CMOS) integrated circuit that has been thinned to 50 μm and occupies less than 1/1000th the volume of a standard implant. With a total size of about 3 mm3, the flexible chip can curve to match the brain's surface. This micro-electrocorticography (µECoG) device contains 65,536 electrodes, 1,024 recording channels, and 16,384 stimulation channels. Because the chip is produced using semiconductor industry manufacturing methods, it is suitable for large-scale production.\n\nThe chip integrates a radio transceiver, a wireless power circuit, digital control electronics, power management, data converters, and the analog components necessary for both recording and stimulation. The external relay station provides power and data communication through a custom ultrawideband radio link that reaches 100 Mbps, a throughput at least 100 times higher than any other wireless BCI currently available. Operating as an 802.11 WiFi device, the relay station effectively bridges any computer to the implant.\n\nBISC incorporates its own instruction set along with a comprehensive software environment, forming a specialized computing system for brain interfaces. The high-bandwidth recording demonstrated in this study allows brain signals to be processed by advanced machine-learning and deep-learning algorithms, which can interpret complex intentions, perceptual experiences, and brain states.\n\n\"By integrating everything on one piece of silicon, we've shown how brain interfaces can become smaller, safer, and dramatically more powerful,\" Shepard says.\n\nAdvanced Semiconductor Fabrication\n\nThe BISC implant was fabricated using TSMC's 0.13-μm Bipolar-CMOS-DMOS (BCD) technology. This fabrication method combines three semiconductor technologies into one chip to produce mixed-signal integrated circuits (ICs). It allows digital logic (from CMOS), high-current and high-voltage analog functions (from bipolar and DMOS transistors), and power devices (from DMOS) to work together efficiently, all of which are essential for BISC's performance.\n\nMoving From the Lab Toward Clinical Use\n\nTo transition the system into real-world medical use, Shepard's group partnered with Youngerman at NewYork-Presbyterian/Columbia University Irving Medical Center. They developed surgical procedures to place the thin implant safely in a preclinical model and confirmed that the device produced high-quality, stable recordings. Short-term intraoperative studies in human patients are already underway.\n\n\"These initial studies give us invaluable data about how the device performs in a real surgical setting,\" Youngerman says. \"The implants can be inserted through a minimally invasive incision in the skull and slid directly onto the surface of the brain in the subdural space. The paper-thin form factor and lack of brain-penetrating electrodes or wires tethering the implant to the skull minimize tissue reactivity and signal degradation over time.\"\n\nExtensive preclinical work in the motor and visual cortices was carried out with Dr. Tolias and Bijan Pesaran, professor of neurosurgery at the University of Pennsylvania, both recognized leaders in computational and systems neuroscience.\n\n\"The extreme miniaturization by BISC is very exciting as a platform for new generations of implantable technologies that also interface with the brain with other modalities such as light and sound,\" Pesaran says.\n\nBISC was developed through the Neural Engineering System Design program of the Defense Advanced Research Projects Agency (DARPA) and draws on Columbia's deep expertise in microelectronics, the advanced neuroscience programs at Stanford and Penn, and the surgical capabilities of NewYork-Presbyterian/Columbia University Irving Medical Center.\n\nCommercial Development and Future AI Integration\n\nTo move the technology closer to practical use, researchers at Columbia and Stanford created Kampto Neurotech, a startup founded by Columbia electrical engineering alumnus Dr. Nanyu Zeng, one of the project's lead engineers. The company is producing research-ready versions of the chip and working to secure funding to prepare the system for use in human patients.\n\n\"This is a fundamentally different way of building BCI devices,\" Zeng says. \"In this way, BISC has technological capabilities that exceed those of competing devices by many orders of magnitude.\"\n\nAs artificial intelligence continues to advance, BCIs are gaining momentum both for restoring lost abilities in people with neurological disorders and for potential future applications that enhance normal function through direct brain-to-computer communication.\n\n\"By combining ultra-high resolution neural recording with fully wireless operation, and pairing that with advanced decoding and stimulation algorithms, we are moving toward a future where the brain and AI systems can interact seamlessly -- not just for research, but for human benefit,\" Shepard says. \"This could change how we treat brain disorders, how we interface with machines, and ultimately how humans engage with AI.\"",
      "url": "https://www.sciencedaily.com/releases/2025/12/251209234139.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-12-10",
      "sentiment_score": 0.95,
      "reasoning": "The article describes a significant breakthrough in brain-computer interface technology with a tiny, minimally invasive chip that can stream neural activity in real time. This innovation has broad potential to improve treatment for neurological conditions such as epilepsy, paralysis, ALS, stroke, and blindness, representing a meaningful positive impact on public health. The story is well-detailed, explaining the technology, clinical progress, and future implications, fulfilling criteria for inspiring good news.",
      "category": "Health",
      "personality_title": "Tiny brain chip streams thoughts wirelessly to aid neurological treatment",
      "personality_presentation": "**Context** – Scientists have been working to create devices that connect the brain directly to computers. These brain-computer interfaces (BCIs) help people with neurological problems by reading brain signals and sometimes sending signals back. Until now, these devices were often bulky and required large implants inside the body.\n\n**What happened** – A group of researchers from Columbia University, Stanford, and other institutions developed a new brain implant called the Biological Interface System to Cortex (BISC). This ultra-thin chip, about the size of a small grain, can be placed between the brain and skull through a small opening. It uses thousands of tiny electrodes to read brain activity and send data wirelessly at very high speeds. The implant connects to a wearable relay that communicates with computers, allowing real-time streaming of thoughts and brain signals.\n\n**Impact** – BISC is much smaller and less invasive than previous devices, making it safer and more comfortable for patients. It can capture detailed brain signals that help decode movement, perception, and intentions. This technology could improve treatments for epilepsy, paralysis, blindness, and other brain disorders by restoring lost abilities or controlling symptoms more effectively. It also uses advanced artificial intelligence to better understand brain activity.\n\n**What's next step** – Researchers are testing BISC in early clinical studies and developing surgical methods to implant it safely. A startup called Kampto Neurotech is working to produce versions of the chip for use in patients and to raise funds for further development. Future work will focus on improving the technology and integrating AI to create more powerful brain-machine communication.\n\n**One-sentence takeaway** – A tiny, wireless brain chip offers a new way to monitor and treat neurological conditions by streaming brain activity in real time with minimal surgery.",
      "personality_title_fr": "Une puce cérébrale minuscule transmet les pensées sans fil pour aider aux traitements neurologiques",
      "personality_presentation_fr": "**Contexte** – Les scientifiques cherchent à créer des dispositifs qui connectent directement le cerveau aux ordinateurs. Ces interfaces cerveau-ordinateur (ICO) aident les personnes souffrant de problèmes neurologiques en lisant les signaux du cerveau et parfois en envoyant des signaux en retour. Jusqu’à présent, ces dispositifs étaient souvent encombrants et nécessitaient de grands implants dans le corps.\n\n**Ce qui s’est passé** – Une équipe de chercheurs de l’Université Columbia, de Stanford et d’autres institutions a développé un nouvel implant cérébral appelé Biological Interface System to Cortex (BISC). Cette puce ultra-fine, de la taille d’un petit grain, peut être placée entre le cerveau et le crâne par une petite ouverture. Elle utilise des milliers de minuscules électrodes pour lire l’activité cérébrale et envoyer des données sans fil à très haute vitesse. L’implant se connecte à un relais portable qui communique avec les ordinateurs, permettant la transmission en temps réel des pensées et des signaux cérébraux.\n\n**Impact** – BISC est beaucoup plus petit et moins invasif que les dispositifs précédents, ce qui le rend plus sûr et plus confortable pour les patients. Il peut capturer des signaux cérébraux détaillés qui aident à décoder les mouvements, les perceptions et les intentions. Cette technologie pourrait améliorer les traitements de l’épilepsie, de la paralysie, de la cécité et d’autres troubles du cerveau en restaurant les capacités perdues ou en contrôlant mieux les symptômes. Elle utilise aussi une intelligence artificielle avancée pour mieux comprendre l’activité cérébrale.\n\n**Prochaine étape** – Les chercheurs testent BISC dans des études cliniques initiales et développent des méthodes chirurgicales sûres pour l’implanter. Une start-up appelée Kampto Neurotech travaille à la production de versions de la puce pour les patients et à la collecte de fonds pour poursuivre le développement. Les travaux futurs viseront à améliorer la technologie et à intégrer l’IA pour créer une communication cerveau-machine plus puissante.\n\n**Message clé en une phrase** – Une puce cérébrale minuscule et sans fil offre une nouvelle façon de surveiller et traiter les troubles neurologiques en transmettant l’activité cérébrale en temps réel avec une chirurgie minimale.",
      "personality_title_es": "Pequeño chip cerebral transmite pensamientos inalámbricamente para ayudar en tratamientos neurológicos",
      "personality_presentation_es": "**Contexto** – Los científicos han estado trabajando para crear dispositivos que conecten el cerebro directamente con computadoras. Estas interfaces cerebro-computadora (BCI) ayudan a personas con problemas neurológicos al leer señales del cerebro y, a veces, enviar señales de regreso. Hasta ahora, estos dispositivos eran grandes y requerían implantes voluminosos dentro del cuerpo.\n\n**Qué pasó** – Un grupo de investigadores de la Universidad de Columbia, Stanford y otras instituciones desarrolló un nuevo implante cerebral llamado Biological Interface System to Cortex (BISC). Este chip ultradelgado, del tamaño de un pequeño grano, puede colocarse entre el cerebro y el cráneo a través de una pequeña abertura. Usa miles de diminutos electrodos para leer la actividad cerebral y enviar datos inalámbricamente a muy alta velocidad. El implante se conecta a un receptor portátil que comunica con computadoras, permitiendo transmitir pensamientos y señales cerebrales en tiempo real.\n\n**Impacto** – BISC es mucho más pequeño y menos invasivo que los dispositivos anteriores, lo que lo hace más seguro y cómodo para los pacientes. Puede captar señales cerebrales detalladas que ayudan a descifrar movimientos, percepciones e intenciones. Esta tecnología podría mejorar tratamientos para epilepsia, parálisis, ceguera y otros trastornos cerebrales al restaurar habilidades perdidas o controlar síntomas más eficazmente. También usa inteligencia artificial avanzada para entender mejor la actividad del cerebro.\n\n**Próximo paso** – Los investigadores están probando BISC en estudios clínicos iniciales y desarrollando métodos quirúrgicos para implantarlo de forma segura. Una startup llamada Kampto Neurotech trabaja en producir versiones del chip para pacientes y en obtener fondos para avanzar en el desarrollo. El trabajo futuro se centrará en mejorar la tecnología e integrar IA para crear una comunicación cerebro-máquina más poderosa.\n\n**Resumen en una frase** – Un chip cerebral pequeño e inalámbrico ofrece una nueva forma de monitorear y tratar condiciones neurológicas transmitiendo la actividad cerebral en tiempo real con cirugía mínima.",
      "image_url": "public/images/news_image_Scientists-reveal-a-tiny-brain-chip-that-streams-t.png",
      "image_prompt": "A delicate, translucent silicon chip shaped like a thin leaf gently resting on the soft, curved surface of a glowing brain silhouette, interconnected by fine, glowing neural threads that flow seamlessly into a nearby stylized wireless relay station emitting gentle waves, all rendered in warm, natural earth tones with intricate, detailed linework evoking harmony between technology and the human mind."
    },
    {
      "title": "Gene-drive-capable mosquitoes suppress patient-derived malaria in Tanzania",
      "summary": "Nature, Published online: 10 December 2025; doi:10.1038/s41586-025-09685-6Engineering of local Anopheles gambiae under containment enables the generation of a transgenic strain equipped with non-autonomous gene drive capabilities that robustly inhibits genetically diverse Plasmodium falciparum isolates obtained from naturally infected children.",
      "content": "Malaria remains a major public health concern, with many African nations being far from meeting their malaria elimination targets4,5. Vector control methods including indoor residual spraying and long-lasting insecticide-treated bed nets have played a pivotal role in reducing malaria incidence, but the emergence of insecticide-resistant mosquitoes has impeded further progress6. In addition, Africa’s rapidly growing population and persistent malaria receptivity make these interventions increasingly unsustainable as standalone solutions. This highlights the urgent need for innovative, self-sustaining and cost-effective technologies to complement existing efforts in malaria elimination. Gene drive technology, which enables the biased inheritance of selected traits and can spread through populations at rates exceeding those predicted by Mendelian genetics, has emerged as a promising new paradigm7,8.\n\nGene drive can offer a transformative solution for malaria elimination by spreading genetic modifications that can either suppress mosquito populations or render them unable to transmit the disease2,9,10. Our work focuses on the latter approach known as mosquito population modification or replacement, whereby antiparasitic effectors introduced into the mosquito genome are spread to fixation within populations using a Cas9 endonuclease-based synthetic gene drive. In our design, the transmission-blocking effector and gene drive functions are separated into distinct genetic traits and strains3,11,12,13. This separation offers several advantages: it allows the development, testing and optimization of effector constructs in endemic settings independently of a full gene drive system; it facilitates rigorous risk assessment and community engagement before introducing self-propagating elements and it provides a safer, more modular pathway towards deployment12. Crucially, evaluating non-autonomous effector strains helps address elevated regulatory and containment requirements associated with autonomous gene drive systems.\n\nGenetic modification of mosquitoes to reduce their vectorial capacity was first attempted more than two decades ago, and dozens of transgenic strains have been described in the literature to date9,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30. However, no effector has ever been evaluated against parasites other than laboratory strains many of which were established in the early 1980s31. For this reason, their propensity to block the transmission of genetically diverse Plasmodium isolates now in circulation is unknown.\n\nWe previously demonstrated the efficacy of one such A. gambiae effector modification in inhibiting the NF54 strain of laboratory-cultured P. falciparum. This modification, termed MM-CP, involves two antimicrobial peptides, magainin 2 from the African clawed frog and melittin from the European honeybee32, integrated into and expressed from within the endogenous zinc carboxypeptidase A1 gene (CP)33. This minimal genetic modification that harbours no fluorescent markers interferes with oocyst development causing a significant delay in the release of infectious sporozoites. It also reduces the lifespan of homozygous female mosquitoes, further minimizing their potential to transmit malaria. Predictive models suggest that gene-drive-mediated population-wide propagation of MM-CP could disrupt disease transmission across various settings, offering promise for malaria elimination even in scenarios in which resistance to the effector or the drive eventually emerge. Here we adapted this technology for an African context to evaluate its ability to suppress P. falciparum parasites naturally circulating among humans.\n\nThe implementation of gene drive technologies in malaria-endemic regions faces substantial challenges, including limited access to appropriate containment infrastructure, regulatory uncertainty, insufficient local capacity for genetic engineering and biosafety, and the imperative for community trust and public transparency. To enable our work, we developed an integrated Modular Portable Laboratory and Containment Level 3 (MPL/CL3) insectary facility, specifically designed for generating, housing and studying genetically modified mosquitoes within an African context (Fig. 1a). The MPL/CL3 was designed to address some of these constraints by offering a high-security and standardized facility tailored to local environmental and regulatory conditions. It incorporates climate and illumination control systems, rearing chambers, microbiologically safety cabinets, water management and waste disposal systems, an autoclaving unit and a fully equipped laboratory. The facility was constructed within two intermodal shipping containers in Spain and transported and installed at the Bagamoyo campus of the Ifakara Health Institute (IHI) in Tanzania (Fig. 1b). By embedding cutting-edge vector biology capacity within endemic settings, the MPL/CL3 supported local research leadership, regulatory readiness and public engagement, laying essential groundwork for responsible development and evaluation of gene drive technologies. Detailed specifications and technical plans are presented in the Methods and Supplementary Note. All protocols involving the generation and study of transgenic mosquitoes were reviewed and approved by the relevant institutional and national regulatory authorities in Tanzania.\n\nFig. 1: Infrastructure capacity building and malaria surveillance sites in northeastern Tanzania. a, Integrated MPL/CL3 facility. Architectural design plans for the (left) and a detailed view of the integrated laboratory and insectary container unit (right) are shown. The laboratory comprises a lobby, an incubator room for mosquito husbandry, a molecular biology laboratory and a dedicated space for P. falciparum DMFAs and housing of infected mosquitoes. The second container unit houses systems that regulate and maintain optimal environmental conditions, including a negative pressure system for biosecurity, water purification and waste treatment. An external electricity generator supports these operations. b, Field sites for parasitological surveys and gametocyte carrier recruitment. Locations of villages in the Pwani region where parasitological surveys were conducted in children are shown in relation to the IHI Bagamoyo campus (housing the MPL/CL3 facility), the capital Dodoma, the major port city Dar es Salaam and the town of Chalinze, where meteorological data were recorded. The map is modified to highlight sites mentioned in the paper. Tanzania road map in b adapted from OnTheWorldMap.com (https://ontheworldmap.com/tanzania/tanzania-road-map.html). Full size image\n\nThe first A. gambiae transgenic line developed onsite within the MPL/CL3, named zpg-CC, was designed to streamline all transgenesis processes by expressing both Cre recombinase and Cas9 endonuclease under the control of the zero-population growth (zpg) gene promoter. This dual helper strain enables the efficient removal of sequences such as transgenesis markers flanked by loxP sites and establishment of transgene homozygosity through homing. The initial development and characterization of the zpg-CC line were conducted at Imperial, before the line was recreated in Tanzania.\n\nThe zpg-CC construct includes a dominant DsRed transgenesis marker, integrated into the kynurenine hydroxylase (kh) gene locus (Extended Data Fig. 1a). Disruption of both copies of the gene results in white-eyed mosquitoes, serving as a recessive phenotypic marker. Although the zpg-CC helper line was robust and fertile, it showed reduced overall fitness, probably due to the disruption of the kh locus and/or the effects of germline-specific or leaky expression of both Cre and Cas9. Compared with wild-type (wt) females, sugar-fed transgenic homozygous zpg-CC females showed a small decline in survival over time (Extended Data Fig. 1b), consistent with previous observations in other mosquitoes34,35. They also laid significantly fewer eggs after blood feeding, with a lower proportion hatching, indicating a reduction in reproductive fitness (Extended Data Fig. 1c).\n\nTo assess the efficiency of the zpg-CC helper line in inducing homing when combined with a non-autonomously driveable transgene expressing guide RNA (gRNA), we crossed heterozygous zpg-CC males with females of a previously generated CP knockout (CP-KO) line that harbour a green fluorescent protein (GFP) expression cassette and a gRNA expression module inserted within and targeting the CP gene36 (Extended Data Fig. 1a). Heterozygous offspring expressing both GFP and DsRed were sib-mated, and the resulting larvae were screened for green fluorescence. All 623 larvae screened were GFP positive, compared with the 75% expected from a Mendelian intercross of hemizygotes. This indicates 100% Cas9-mediated homing, induced by Cas9 provided by the zpg-CC helper line (Extended Data Fig. 1d).\n\nNext, we assessed the capacity of the zpg-CC helper line to excise a loxP-flanked GFP expression cassette through the expression of Cre recombinase. As a tester line we used the zpg-Cas9GFP strain, in which a Cas9 coding sequence was inserted within the zpg gene to encode Cas9 linked to the zpg C terminus through an E2A ribosome-skipping peptide sequence. An intron harbouring the excisable GFP expression cassette flanked by loxP sites and a gRNA module is located within the E2A sequence (Extended Data Fig. 1a). We crossed zpg-Cas9GFP males with heterozygous zpg-CC females, selecting GFP and DsRed positive males for subsequent crosses with wt females (Extended Data Fig. 1e). Among 417 offspring larvae, only 13 showed green fluorescence, indicating efficient Cre-mediated excision of the GFP cassette (97%).\n\nThese experiments confirmed efficient Cas9 and Cre expression by the zpg-CC helper strain. We therefore recreated the zpg-CC line in Tanzania, by microinjecting embryos of the A. gambiae Ifakara strain37 with the zpg-CC plasmid together with independent Cas9 and gRNA helper plasmids. G 0 larvae showing transient fluorescence were allowed to mature into adults that were then crossed with wt mosquitoes in separate male and female crosses (Fig. 2). These crosses produced 28 G 1 transgenic larvae expressing DsRed in the nervous tissue, of which 25 (16 males, 9 females) reached adulthood. After four rounds of backcrossing with wt mosquitoes, a pure and stable colony was established by continuously selecting larvae showing DsRed fluorescence and kh locus disruption, indicated by the absence of eye pigments. Despite Cas9 expression, these mosquitoes cannot autonomously propagate their modification through gene drive, as they lack genomic integration of a gRNA gene.\n\nFig. 2: Schematic representation of the strategy for the generation of a markerless, homozygous MM-CP line. This approach involved a series of breeding and selection steps, detailed as follows in a clockwise progression. Top left, tabular summary of the processes for generating the zpg-CC and MM-CPGFP transgenic lines. Top middle, each transgenic line was outcrossed with the wt Ifakara strain to enhance line vigour. Top right, strains were maintained through sibling mass crossing to preserve genetic stability. Bottom right, MM-CPGFP females were crossed with zpg-CC males, and double-positive individuals (GFP and DsRed) were selected and mass-bred. Bottom middle, this process enabled Cre-mediated removal of the GFP expression cassette (floxing) and Cas9-driven homozygosity of the MM-CP transgene (homing). Bottom left, non-fluorescent individuals were selected for pupal case genotyping to identify homozygous MM-CP individuals. These homozygous mosquitoes were then mass-bred to establish the MM-CP line, subsequently used in homing and P. falciparum DMFA infection assays. eGFP, enhanced GFP. Full size image\n\nNext, we generated the MM-CP line by microinjecting A. gambiae wt Ifakara embryos with the MMGFP-CP plasmid, containing a gRNA for integration into the CP locus and a Cas9 source38. This resulted in a single G 1 transgenic male expressing GFP in the eyes and ganglia, which was then backcrossed with wt mosquitoes for four generations to establish a stable MMGFP-CP precursor line (Fig. 2). To achieve transgene homozygosity and remove the GFP marker cassette, MMGFP-CP females were crossed with zpg-CC males and double fluorescent progeny were sib-mated. The resulting colony carried the antimalarial MM-CP transgene as a minimal, markerless modification. Molecular genotyping confirmed that most mosquitoes in the colony were homozygous for the transgene (Fig. 2).\n\nTo quantify MM-CP inheritance rates in the presence of Cas9, we crossed MM-CP females with zpg-CC males (which express Cas9) and vice versa (Fig. 3a). Equivalent crosses with wt mosquitoes served as controls. The resulting F 1 zpg-CC;MM-CP and +;MM-CP heterozygotes from these experimental crosses were then separately crossed with wt mosquitoes, with male and female G 1 individuals crossed independently. We conducted three replicates for each cross and genotyped 20 F 2 progeny per replicate to assess the presence of the MM-CP transgene in a heterozygous state (Extended Data Table 1). Both male and female MM-CP;zpg-CC crosses with wt mosquitoes showed high inheritance rates of the MM-CP transgene to F 2 progeny, averaging 94.2 ± 4.9%, compared with the control crosses (MM-CP females crossed to wt males), which showed near-Mendelian segregation at 48.3 ± 4.1% (Fig. 3a). These results indicate high rates of non-autonomous gene drive of the MM-CP transgene when combined with germline Cas9 expression.\n\nFig. 3: Transmission efficiency and life history traits of MM-CP Ifakara mosquitoes. a, Schematic of the non-autonomous homing assay used to evaluate transmission efficiency of the MM-CP transgene. Homozygous MM-CP females were crossed with either zpg-CC males (Cas9 source) or wt Ifakara males (control). F 1 progeny were sexed and reciprocally crossed with wt Ifakara mosquitoes. Twenty F 2 progeny per cross (in triplicate) were genotyped by PCR to detect the MM-CP transgene. The bar graph (far right) shows inheritance rates, with significantly higher MM-CP transmission in zpg-CC crosses, confirming efficient non-autonomous homing. Each row represents a biological replicate, and each box denotes one mosquito (5% rate). Note that only 17 mosquitoes were genotyped in 1 replicate. b, Fecundity of MM-CP (n = 23 and 25) and wt (n = 25 and 24) females, measured as the number of eggs laid per mosquito in two independent biological replicates. MM-CP females showed significantly reduced egg output compared with wt controls (P = 0.0005, two-sided Mann–Whitney U-test). Boxplots show median, interquartile range (25th to 75th percentiles) and full data range (whiskers) for each group; dots outside boxplots are outliers. Source data are provided in Source Data Sheet 1. c, Mean fertility of female mosquitoes used for the fecundity assays (b), measured as hatching rate (% of eggs developing into larvae), did not differ significantly between lines (P = 0.95, two-sided Mann–Whitney U-test). Error bars show the range of fertility rates across the two replicates. Source data are provided in Source Data Sheet 1. d, Survival curves postemergence. Left, females post-bloodmeal (BF); right, sugar-fed males. MM-CP females showed markedly reduced survival after blood feeding (P < 0.0001, log-rank test); males also showed reduced survival under sugar-only conditions (P < 0.0001), although to a lesser extent. Data points represent the mean of two independent biological replicates (MM-CP, n = 378 and 242; wt, n = 368 and 350), each comprising three cages of mosquitoes reared from separate aquatic trays. Error bars indicate the range between replicates. Source data are provided in Source Data Sheet 2. Full size image\n\nMM-CP mosquitoes originally generated in a mixed KIL/G3 genetic background showed reduced fitness, including lower fecundity and decreased survival, particularly in females38. KIL and G3 are two genetically distinct A. gambiae laboratory strains colonized from northern Tanzania and The Gambia in the 1970s, respectively. Life history assays with the new MM-CP line in the A. gambiae Ifakara background yielded similar results, confirming that these phenotypes are consistent across genetic backgrounds, an important consideration for gene drive deployment. Specifically, MM-CP females laid significantly fewer eggs than controls (Fig. 3b), although hatching rates were comparable (Fig. 3c). Survival was reduced in both sexes, with the most pronounced effect observed in females following a bloodmeal (Fig. 3d). Although some survival effects may reflect inbreeding from the transgenesis process and are unlikely to persist under gene drive conditions involving continuous outcrossing, the sharp post-bloodmeal decline in female survival is probably driven by strong antimicrobial peptide expression at the bloodmeal-inducible CP locus or perturbations of CP expression due to the antimicrobial peptide integration. This phenotype is modelled to enhance the efficacy of the intervention by reducing the likelihood that infected females survive long enough to transmit the disease38. Despite these fitness costs, multi-generational cage experiments have demonstrated that MM-CP can still be driven efficiently to near-fixation when combined with a self-propagating Cas9 source, supporting the robustness of MM-CP under gene drive rconditions39.\n\nNext, we proceeded to assess the efficacy of the locally developed MM-CP strain in inhibiting parasites circulating among infected children. We conducted surveys in primary school pupils in Wami Mkoko and Miono Kikalo villages to determine the levels of parasitaemia and gametocytaemia (Fig. 2b). These surveys were later expanded to include children aged 6–14 in Kibindu village. Malaria infection was determined using rapid diagnostic testing (RDT), with parasites quantified through thick blood smear microscopy. Written informed consents were obtained from parents or guardians, and oral assent was secured from children. These activities were conducted alongside structured community engagement to promote transparency, address concerns and foster public trust. The results indicated year-round malaria transmission, with parasitaemia and gametocytaemia present in roughly 25–30% and 2–5% of screened children, respectively (Fig. 4a). The high malaria prevalence throughout the survey period may be linked to the 2023–2024 El Niño-Southern Oscillation that occurred between July 2023 and April 2024 and was associated with significantly more rainfall in this part of the country40. To ensure that a diverse array of parasite genotypes were circulating in these three villages, we sequenced four genes (CSP, AMA1, SERA2 and TRAP) known to provide a robust measure of P. falciparum diversity41. The results confirmed that our sampling strategy captured a representative diversity of genotypes in these communities (Fig. 4b).\n\nFig. 4: P. falciparum epidemiology and phylogenetic analysis. a, Epidemiological data on P. falciparum parasitaemia and gametocytaemia among children in three villages within the Pwani region. The bottom x axis indicates screening dates, the top x axis indicates the number of children screened each day, and the y axis shows the percentage of parasitaemic and percentage of gametocytaemic children among the total number of children screened on each date. The total number of children screened per date is shown above the graph. Dates when gametocytaemic blood samples (one per date) were used for successful mosquito infections are indicated, with corresponding results reported in referenced figure panels. The blue gradient in the background represents the 60-day cumulative rainfall (mm) before each survey, recorded at the Chalinze meteorological station, and the gradient below the graph (yellow to blue) shows the difference in rainfall (mm) compared with the same period 1 year earlier. Screening dates when gametocytaemic blood was collected for the mosquito infection replicates (r1–5) presented in Fig. 5 are indicated. Source data are provided in Source Data Sheet 3. b, Phylogenetic tree of P. falciparum isolates obtained from 1–2 gametocytaemic children on most screening days. Consensus sequences of the CSP, AMA1, SERA2 and TRAP genes were concatenated and aligned to assess genetic relatedness. Each tip label shows the sample ID, collection date and percentage sequence identity to the P. falciparum NF54 reference genome. Coloured labels correspond to isolates used for mosquito infection experiments and are matched to their respective village of origin as shown in a. The scale bar represents sequence divergence, expressed as the square root of percentage sequence divergence. Raw sequencing data are available under BioProject accession PRJNA1299763 (NCBI SRA). Full size image\n\nChildren with high gametocyte densities were invited to provide blood samples for mosquito direct membrane feeding assays (DMFAs). Previous studies have shown that infection outcomes from DMFAs correlate closely with those from direct skin feeding, supporting their biological relevance42,43. Of numerous DMFAs conducted, five produced significant oocyst numbers and were processed further. The first three infections were used to assess oocyst counts and sizes at 9 days postfeeding, whereas the last two replicates served to quantify sporozoite loads in mosquito midgut and head and/or thorax tissues using real-time quantitative PCR (qPCR) at 13–15 days postfeeding. The parasite genotypic analysis confirmed that isolates used for the first three experiments diverge from the NF54 reference genome and from each other (Fig. 4b). Isolates used in the last two infection experiments were not sequenced.\n\nMicroscopy showed that most MM-CP mosquito midguts contained notably smaller oocysts (Fig. 5a), consistent with what was previously observed in KIL/G3 MM-CP mosquitoes infected with laboratory P. falciparum38. Quantitative measurements indicated a median oocyst diameter of 22.2 µm in MM-CP compared with 57.3 µm in wt midguts (Fig. 5b). However, some MM-CP mosquitoes also contained larger oocysts, similar in size to those in wt mosquitoes. Molecular genotyping of mosquito carcasses revealed that these midguts derived from heterozygous MM-CP or non-transgenic mosquitoes present in the MM-CP colony (Fig. 5c).\n\nFig. 5: Effect of MM-CP transgenic mosquitoes on P. falciparum oocyst growth and sporozoite output. a, Representative images of mercurochrome-stained midguts from wt and MM-CP transgenic mosquito lines at 9 days post-infectious bloodmeal (dpi), showing marked differences in oocyst size. Insets show magnified regions of oocyst clusters. b, Quantification of oocyst diameters in midguts from wt (n = 19, n = 37 and n = 17, respectively) and MM-CP (n = 25, n = 29 and n = 21, respectively) mosquitoes from three independent infections experiments using P. falciparum gametocytes from infected children. The leftmost plot shows pooled data from all replicates (r1–3) and the remaining plots show data from each replicate individually. Boxplots show median, interquartile range and full data range (whiskers) for each group; dots outside the boxplots are outliers. Significance was tested using the Kruskal–Wallis H-test (****P < 0.0001; effect size η2 = 0.355). Note that some variability in oocyst size is also visible in wt midguts, reflecting natural variation commonly observed in wt infections. Source data are provided in Source Data Sheet 4. c, Oocyst diameters in midguts of the MM-CP line classified by genotype: homozygous MM-CP (orange circles), heterozygous MM-CP/+ (yellow squares) or wt+/+ (grey circles). Note that all oocysts in wt mosquitoes originate from only two midguts, cautioning against any interpretations of size differences relative to heterozygous mosquitoes. Source data are provided in Source Data Sheet 4. d, Sporozoite data in wt and MM-CP mosquitoes from the fourth infection replicate (r4) assayed at 13–15 dpi. Left, prevalence of midgut sporozoites. Middle, prevalence of sporozoites in head and/or thorax tissues (used as salivary (sal.) glands proxy). Each shaded box represents 5% prevalence. Total numbers assayed and positives are shown. Right, dot plot showing relative sporozoite abundance in head and/or thorax samples. Source data are provided in Source Data Sheet 5. e, Same analyses as in d, shown for the fifth replicate (r5). Note that between the third and fourth replicates, the colony was further cleaned using pupal case genotyping to enrich for MM-CP homozygotes. Source data are provided in Source Data Sheet 5. Scale bars, 100 µm. Full size image\n\nTo improve the consistency of phenotypic analyses, we enriched the MM-CP transgene in the colony by implementing a pupal case genotyping strategy to identify and select homozygous individuals, thereby eliminating wt alleles at the CP locus and increasing the proportion of MM-CP homozygotes. In the fourth and fifth replicates, mosquitoes were dissected 13–15 days post-infective bloodmeal, and parasite detection was conducted through qPCR targeting the 18S ribosomal subunit in genomic DNA extracted from midguts and separately from head and/or thorax tissues for those mosquitoes that tested positive for midgut parasites.\n\nResults from the fourth replicate indicated that although 36 (85%) of 42 MM-CP mosquitoes had detectable parasites in their midguts, none (0%) tested positive for parasites in their head and/or thorax, a proxy for salivary gland infection (Fig. 5d). By contrast, 82 (57%) of 143 wt control mosquitoes were midgut positive and 50 (35%) had head and/or thorax parasite presence, showing variable sporozoite loads. Similarly, in the fifth replicate, 56 (54%) of 104 MM-CP mosquitoes tested positive for midgut infection, but only 7 (7%) tested positive for salivary gland infection, all with very low infection levels (Fig. 5e). This contrasts with 104 wt mosquitoes of which 66 (63%) were midgut positive and 57 (55%) showed salivary gland infection.\n\nThese findings demonstrate that our earlier observations from a different A. gambiae MM-CP genetic background infected with the laboratory P. falciparum NF54 strain38, characterized by reduced and delayed sporozoite development, impaired oocyst maturation and limited salivary gland invasion, are recapitulated when MM-CP mosquitoes are challenged with genetically diverse P. falciparum isolates from malaria patients. This highlights the robustness of the MM-CP phenotype across parasite genotypes and reinforces its potential for impact under real-world transmission settings. Although we cannot fully exclude the possibility that low-level sporozoite development may eventually lead to transmission, the combination of delayed parasite maturation and reduced post-bloodmeal mosquito survival is projected to severely constrain the likelihood of onwards transmission under field conditions.",
      "url": "https://www.nature.com/articles/s41586-025-09685-6",
      "source": "Nature",
      "published": "2025-12-11",
      "sentiment_score": 0.95,
      "reasoning": "The article reports a significant scientific breakthrough in malaria control using gene-drive-capable genetically modified mosquitoes that inhibit transmission of diverse malaria parasites in Tanzania. This technology has broad public health implications for malaria-endemic regions, addressing a major global health challenge. The study includes detailed context, experimental validation, local capacity building, and community engagement, demonstrating substance and real-world impact.",
      "category": "Health",
      "personality_title": "Genetically modified mosquitoes block malaria parasites in Tanzania",
      "personality_presentation": "**Context** – Malaria is a serious disease spread by mosquitoes, especially in Africa. Traditional methods like insecticide-treated nets are losing effectiveness because mosquitoes are becoming resistant. Scientists need new ways to stop malaria from spreading.\n\n**What happened** – Researchers in Tanzania created special genetically modified mosquitoes using a technology called gene drive. These mosquitoes carry a genetic change that stops malaria parasites from growing inside them. The team built a secure lab in Tanzania to develop and test these mosquitoes with malaria parasites taken from local children. Their tests showed that these modified mosquitoes had much smaller malaria parasites and fewer infectious parasites in their bodies compared to normal mosquitoes.\n\n**Impact** – This is the first time genetically modified mosquitoes have been shown to block malaria parasites taken directly from patients, not just lab strains. It proves that gene drive mosquitoes can work in real-world conditions to reduce malaria spread. The project also built local scientific skills and involved the community, which is important for safely using this technology in the future.\n\n**What’s next step** – Scientists will continue to improve these mosquitoes and test them in controlled environments. They will also work with regulators and communities to prepare for possible field trials. The goal is to eventually release these mosquitoes to help reduce malaria cases where it is still a big problem.\n\n**One-sentence takeaway** – Genetically modified mosquitoes developed in Tanzania can block local malaria parasites, offering a promising new tool to fight malaria.\n",
      "personality_title_fr": "Des moustiques génétiquement modifiés bloquent les parasites du paludisme en Tanzanie",
      "personality_presentation_fr": "**Contexte** – Le paludisme est une maladie grave transmise par les moustiques, surtout en Afrique. Les méthodes traditionnelles comme les moustiquaires insecticides deviennent moins efficaces car les moustiques développent une résistance. Il faut donc de nouvelles solutions pour arrêter la propagation du paludisme.\n\n**Ce qui s’est passé** – Des chercheurs en Tanzanie ont créé des moustiques génétiquement modifiés grâce à une technologie appelée « gene drive ». Ces moustiques portent un changement génétique qui empêche le développement des parasites du paludisme en eux. L’équipe a construit un laboratoire sécurisé en Tanzanie pour développer et tester ces moustiques avec des parasites prélevés chez des enfants locaux. Les tests ont montré que ces moustiques modifiés avaient des parasites beaucoup plus petits et moins infectieux que les moustiques normaux.\n\n**Impact** – C’est la première fois que des moustiques génétiquement modifiés bloquent des parasites du paludisme issus directement de patients, pas seulement des souches de laboratoire. Cela prouve que ces moustiques peuvent fonctionner dans des conditions réelles pour réduire la transmission du paludisme. Le projet a aussi renforcé les compétences scientifiques locales et impliqué la communauté, ce qui est essentiel pour une utilisation sûre de cette technologie.\n\n**Prochaine étape** – Les scientifiques vont continuer à améliorer ces moustiques et les tester dans des environnements contrôlés. Ils travailleront aussi avec les autorités et les communautés pour préparer d’éventuels essais sur le terrain. L’objectif est de libérer ces moustiques pour diminuer les cas de paludisme dans les zones touchées.\n\n**Résumé en une phrase** – Des moustiques génétiquement modifiés développés en Tanzanie peuvent bloquer les parasites locaux du paludisme, offrant un nouvel outil prometteur contre la maladie.\n",
      "personality_title_es": "Mosquitos genéticamente modificados bloquean parásitos de malaria en Tanzania",
      "personality_presentation_es": "**Contexto** – La malaria es una enfermedad grave transmitida por mosquitos, especialmente en África. Los métodos tradicionales como las redes con insecticidas están perdiendo eficacia porque los mosquitos se vuelven resistentes. Se necesitan nuevas formas de detener la propagación de la malaria.\n\n**Qué pasó** – Investigadores en Tanzania crearon mosquitos genéticamente modificados usando una tecnología llamada gene drive. Estos mosquitos tienen un cambio genético que impide que los parásitos de la malaria crezcan dentro de ellos. El equipo construyó un laboratorio seguro en Tanzania para desarrollar y probar estos mosquitos con parásitos tomados de niños locales. Las pruebas mostraron que estos mosquitos modificados tenían parásitos mucho más pequeños y menos infecciosos que los mosquitos normales.\n\n**Impacto** – Es la primera vez que mosquitos modificados genéticamente bloquean parásitos de malaria tomados directamente de pacientes, no solo cepas de laboratorio. Esto demuestra que los mosquitos gene drive pueden funcionar en condiciones reales para reducir la malaria. El proyecto también fortaleció las capacidades científicas locales e involucró a la comunidad, lo cual es importante para usar esta tecnología de forma segura.\n\n**Próximo paso** – Los científicos seguirán mejorando estos mosquitos y probándolos en ambientes controlados. También trabajarán con reguladores y comunidades para preparar posibles ensayos en campo. La meta es liberar estos mosquitos para ayudar a reducir casos de malaria donde sigue siendo un problema.\n\n**Resumen en una frase** – Mosquitos genéticamente modificados desarrollados en Tanzania pueden bloquear parásitos locales de malaria, ofreciendo una nueva herramienta prometedora para combatir la enfermedad.\n",
      "image_url": "public/images/news_image_Gene-drive-capable-mosquitoes-suppress-patient-der.png",
      "image_prompt": "A detailed, warm-toned painting of stylized mosquitoes with subtle glowing genetic strands in their wings flying peacefully above a vibrant Tanzanian village landscape, with symbolic representations of shrinking malaria parasites as small, fading red spheres beneath the mosquitoes, all rendered in natural earthy colors and soft light."
    },
    {
      "title": "Simple supplement mix shows remarkable results in brain cancer",
      "summary": "New research is challenging one of medicine’s oldest assumptions: that cancer must be attacked to be cured. By treating glioblastoma patients with a simple combination of resveratrol and copper, the researchers found dramatic reductions in tumor aggressiveness, cancer biomarkers, immune checkpoints, and stem-cell–related markers—all without side effects. Their approach focuses on “healing” tumors by eliminating harmful cell-free chromatin particles released from dying cancer cells, which normally inflame and worsen the disease. The findings hint at a future where inexpensive nutraceuticals could transform cancer therapy.",
      "content": "Most cancer treatments, including chemotherapy, radiotherapy and immunotherapy, are designed to attack and destroy cancer cells. A growing group of researchers is now asking whether this long-standing approach may be missing something important. What if the real path to a cure is not to damage cancer, but to coax it into healing instead?\n\nThat provocative idea is at the heart of work led by Professor Indraneel Mittra at the Advanced Centre for Treatment, Research and Education in Cancer in Mumbai, India.\n\nThe concept is not completely new. In 1986, an article in the New Journal of Medicine by Dr. Harold Dvorak suggested that cancer behaves very much like a wound that never heals. Cancer and chronic wounds share many biological features, and Professor Mittra argues that, rather than always trying to destroy tumors, medicine should explore ways to help them move toward a healed, less aggressive state.\n\nIn a recent study involving people with glioblastoma, one of the most feared brain cancers, his team reports that a simple combination of two low-cost nutraceuticals appears to support exactly this kind of healing process.\n\nTesting a Gentle Strategy in Glioblastoma\n\nGlioblastoma is a fast-growing, highly aggressive brain tumor. Even with modern treatments such as surgery, chemotherapy and radiotherapy, used alone or together, patients typically survive a median of only about 15 months.\n\nIn the new study, published in BJC Reports, Professor Mittra and colleagues enrolled ten patients with glioblastoma and asked them to take a tablet containing small amounts of two nutraceuticals, resveratrol and copper. They took this tablet four times a day for an average of 11.6 days before their scheduled brain surgery.\n\nAnother group of ten patients, whose tumors were similarly aggressive but who did not receive resveratrol and copper, served as the control group.\n\nDuring surgery, the team collected brain tumor samples from both groups. These samples were then examined in detail using microscopy, immune-staining, immunofluorescence and transcriptome analysis to see how the tumors differed.\n\nThe analyses showed that the nutraceutical tablets had a striking effect on tumor biology.\n\nDramatic Changes Inside the Tumors\n\nSeveral key cancer markers shifted in a favorable direction in patients who received the resveratrol and copper tablets:\n\nAverage levels of the protein Ki-67, a widely used indicator of how quickly glioblastoma cells are dividing, were almost one third lower in treated tumors than in untreated ones. This suggests the cancer was growing less aggressively.\n\nBiomarkers associated with nine major \"hallmarks of cancer\" were present in 57% fewer cells in the treated samples.\n\nLevels of six immune checkpoints, proteins that normally prevent the immune system from attacking cancer cells, were on average 41% lower in the treated tumors.\n\nThree markers linked to stem cells, which may help tumors spread and resist treatment, were 56% lower in the treated group.\n\nCrucially, the patients who took the nutraceutical tablets did not experience any side-effects.\n\n\"These results suggest that a simple, inexpensive and non-toxic nutraceutical tablet potentially has the power to heal glioblastoma,\" said Professor Mittra.\n\nTargeting Cell-Free Chromatin Particles (cfChPs)\n\nSo how might this apparent healing happen at the cellular level?\n\nAccording to Professor Mittra, the key action involves resveratrol and copper acting on cell-free chromatin particles (cfChPs) (cfChPs) that circulate in the body. These are fragments of DNA released from dying cancer cells that can worsen the behavior of surviving cancer cells.\n\nEarlier work from his group showed that when resveratrol and copper are combined, they generate oxygen radicals that deactivate or destroy cfChPs.\n\nIn the current study, the researchers found that cfChPs were abundant in tissue taken from untreated tumors, but were almost completely absent from tissue taken from tumors in patients who had received the nutraceutical tablets.\n\nThe findings suggest that dead cancer cells in the treated group were removed through apoptosis, a controlled cell death process, before they could release cfChPs into the surrounding environment.\n\nProfessor Mittra explains: \"The cell-free chromatin particles, fragments of DNA released by dying cancer cells, inflame the surviving cancer cells. This makes the disease more aggressive.\n\n\"If you eliminate the cell-free chromatin, which is what the resveratrol-copper tablets do, the cancer is subdued.\"\n\nHe adds that with longer-term use, this approach might possibly lead to complete healing of the cancer, effectively turning a malignant tumor into a benign one.\n\nImmune Checkpoints and a Low Cost Alternative\n\nOne of the most notable findings from the study is that the resveratrol-copper tablets reduced the activity of several immune checkpoints. Immune checkpoint inhibition has been hailed as a breakthrough in cancer therapy, because blocking these proteins can unleash the immune system against tumors. However, current immune checkpoint inhibitor drugs are extremely expensive and can cause significant side-effects.\n\nIn contrast, the nutraceutical combination used in this study is simple, non-toxic and inexpensive, yet still appears to downregulate multiple immune checkpoints. This raises the possibility of a more accessible way to influence some of the same pathways targeted by costly cancer drugs.\n\nA Potential Shift in Cancer Treatment\n\nA new approach to treating cancer has begun to emerge from these observations.\n\n\"We have been trying to kill cancer cells for 2,500 years, since the time of the ancient Greeks, without success,\" says Professor Mittra.\n\n\"Maybe it is time to look at cancer treatment differently and work towards healing tumors, rather than annihilating them.\n\n\"Of course, the number of patients in this study was rather small. However, the results were so striking that I'd fully expect them to be replicated in a larger sample of patients.\n\n\"I believe that we may be on the brink of transforming the way cancer is treated.\"\n\nProfessor Indraneel Mittra is Dr. Ernest Borges Chair in Translational Research and Professor Emeritus in the Department of Surgical Oncology at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Mumbai.\n\nThis study was supported by the Department of Atomic Energy, Government of India, through its grant CTCTMC to the Tata Memorial Centre awarded to Indraneel Mittra.",
      "url": "https://www.sciencedaily.com/releases/2025/12/251209043050.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-12-10",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant medical breakthrough in treating glioblastoma, a highly aggressive brain cancer, using a simple, inexpensive, and non-toxic supplement combination that reduces tumor aggressiveness and immune suppression without side effects. This approach challenges traditional cancer treatment paradigms and could have broad, meaningful impact on cancer therapy accessibility and outcomes.",
      "category": "Health",
      "personality_title": "Simple supplement mix reduces brain cancer aggressiveness without side effects",
      "personality_presentation": "**Context** – Glioblastoma is a very aggressive brain cancer with limited treatment options and a median survival time of about 15 months. Most current cancer treatments try to kill cancer cells, but researchers are exploring new ways to help tumors heal instead of just attacking them.\n\n**What happened** – A team led by Professor Indraneel Mittra in Mumbai tested a tablet containing two natural substances, resveratrol and copper, on ten glioblastoma patients before surgery. Another ten patients did not take the supplement. The researchers compared tumor samples from both groups and found that tumors from patients who took the supplement grew less quickly and showed fewer signs of aggressive cancer.\n\n**Impact** – The supplement lowered several important cancer markers, including those linked to tumor growth, immune system suppression, and cancer stem cells. It also reduced harmful DNA fragments called cell-free chromatin particles that usually make cancer worse. Importantly, the patients experienced no side effects. This suggests a simple, low-cost way to help control aggressive brain tumors.\n\n**What's next step** – The researchers want to test this supplement combination in more patients to confirm the results. If successful, this method could change how cancer is treated by focusing on healing tumors rather than destroying them. It might also offer an affordable alternative to expensive cancer drugs.\n\n**One-sentence takeaway** – A low-cost mix of natural supplements has shown promising results in reducing glioblastoma aggressiveness safely, pointing to a potential new way to treat brain cancer.\n",
      "personality_title_fr": "Un simple mélange de suppléments réduit l’agressivité du cancer du cerveau sans effets secondaires",
      "personality_presentation_fr": "**Contexte** – Le glioblastome est un cancer du cerveau très agressif avec peu d’options de traitement et un temps de survie moyen d’environ 15 mois. La plupart des traitements actuels visent à tuer les cellules cancéreuses, mais des chercheurs explorent de nouvelles façons d’aider les tumeurs à guérir plutôt que de simplement les attaquer.\n\n**Ce qui s’est passé** – Une équipe dirigée par le professeur Indraneel Mittra à Mumbai a testé un comprimé contenant deux substances naturelles, le resvératrol et le cuivre, sur dix patients atteints de glioblastome avant leur opération. Dix autres patients n’ont pas pris ce supplément. Les chercheurs ont comparé les échantillons de tumeurs des deux groupes et ont constaté que les tumeurs des patients traités poussaient moins vite et présentaient moins de signes de cancer agressif.\n\n**Impact** – Le supplément a réduit plusieurs marqueurs importants du cancer, notamment ceux liés à la croissance tumorale, à la suppression du système immunitaire et aux cellules souches cancéreuses. Il a aussi diminué des fragments d’ADN nuisibles appelés particules chromatiques libres qui aggravent habituellement le cancer. Les patients n’ont pas eu d’effets secondaires. Cela suggère un moyen simple et peu coûteux de mieux contrôler les tumeurs cérébrales agressives.\n\n**Prochaine étape** – Les chercheurs souhaitent tester cette combinaison de suppléments sur un plus grand nombre de patients pour confirmer les résultats. Si cela réussit, cette méthode pourrait changer la façon de traiter le cancer en se concentrant sur la guérison des tumeurs plutôt que leur destruction. Elle pourrait aussi offrir une alternative abordable aux médicaments anticancéreux coûteux.\n\n**Une phrase clé** – Un mélange naturel peu coûteux a montré des résultats prometteurs pour réduire en toute sécurité l’agressivité du glioblastome, ouvrant la voie à un nouveau traitement du cancer du cerveau.\n",
      "personality_title_es": "Una mezcla simple de suplementos reduce la agresividad del cáncer cerebral sin efectos secundarios",
      "personality_presentation_es": "**Contexto** – El glioblastoma es un cáncer cerebral muy agresivo con pocas opciones de tratamiento y una supervivencia media de unos 15 meses. La mayoría de los tratamientos actuales intentan matar las células cancerosas, pero los investigadores están explorando nuevas formas de ayudar a que los tumores sanen en lugar de solo atacarlos.\n\n**Qué pasó** – Un equipo dirigido por el profesor Indraneel Mittra en Mumbai probó una tableta que contenía dos sustancias naturales, resveratrol y cobre, en diez pacientes con glioblastoma antes de la cirugía. Otros diez pacientes no tomaron el suplemento. Los investigadores compararon muestras de tumores de ambos grupos y encontraron que los tumores de los pacientes que tomaron el suplemento crecían más lentamente y mostraban menos signos de cáncer agresivo.\n\n**Impacto** – El suplemento redujo varios marcadores importantes del cáncer, incluidos los relacionados con el crecimiento tumoral, la supresión del sistema inmunológico y las células madre cancerosas. También disminuyó fragmentos dañinos de ADN llamados partículas cromatínicas libres que normalmente empeoran el cáncer. Los pacientes no tuvieron efectos secundarios. Esto sugiere una forma simple y económica de controlar mejor los tumores cerebrales agresivos.\n\n**Próximo paso** – Los investigadores quieren probar esta combinación de suplementos en más pacientes para confirmar los resultados. Si tiene éxito, este método podría cambiar la forma de tratar el cáncer al centrarse en sanar los tumores en lugar de destruirlos. También podría ofrecer una alternativa asequible a los costosos medicamentos contra el cáncer.\n\n**Una frase clave** – Una mezcla natural y económica ha mostrado resultados prometedores para reducir de manera segura la agresividad del glioblastoma, señalando un posible nuevo tratamiento para el cáncer cerebral.\n",
      "image_url": "public/images/news_image_Simple-supplement-mix-shows-remarkable-results-in-.png",
      "image_prompt": "A detailed, warm painting of a delicate brain-shaped garden where vibrant, healthy plants gently surround and transform fading, darkened tumor-like clusters, with glowing red and copper-hued threads symbolizing resveratrol and copper weaving through and healing the damaged areas, set against a soft, natural color palette."
    },
    {
      "title": "Fasting boosts breast cancer therapy efficacy via glucocorticoid activation",
      "summary": "Nature, Published online: 10 December 2025; doi:10.1038/s41586-025-09869-0Beneficial effects of fasting combined with endocrine therapy for oestrogen receptor-α-expressing breast cancers can be recapitulated using exogenous glucocorticoid receptor ligands instead of fasting to reduce harmful effects.",
      "content": "Animal experiments\n\nAll mouse experiments were performed in accordance with institutional guidelines for animal care and use established in the Principles of Laboratory Animal Care (directive 86/609/EEC). Animal work was only initiated upon approval by the Italian Istituto Superiore di Sanità (ISS) with authorization no. 40/2022, protocol 22418.167 or by the Animal Ethics Committee of the Netherlands Cancer Institute. Six-to-eight-week-old female athymic nude mice (purchased from Envigo) were used in the experiments at the Animal Facility of the IRCCS Ospedale Policlinico San Martino (Genoa). These mice were housed in Sealsafe Plus GM500 individually ventilated cages (IVCs) held on DGM Racks at 22 ± 2 °C and approximately 50–60% relative humidity under a 12 h:12 h light:dark lighting cycle and with food (standard diet, 4RF18, Mucedola) and water ad libitum. Mice were acclimatized for one week before experiments were initiated. To allow MCF7 xenograft growth, a 17β-oestradiol-releasing pellet (Innovative Research of America) was inserted in the intra-scapular subcutaneous region under anaesthesia conditions, the day before cell injection. Xenografts were established by subcutaneous injection of 5 × 106 MCF7 cells to both flanks of the mouse (experiments in Figs. 1a,b, 2 and 4a,b), or orthotopic injection of 3 × 106 MCF7 cells into the fourth abdominal fat pad (experiments in Fig. 4d and Extended Data Fig. 3a,b). Treatment was initiated when the tumours appeared as established palpable masses (~2 weeks after cell injection). In each experiment, mice were randomly assigned to receive one of the following treatments or their combinations, as indicated: control (ad libitum diet); TMX (45 mg kg−1 per day in peanut oil, oral gavage3,39), fasting (water only, for 48 h every week3,40), Dexa (4 mg kg−1 every other day in physiological solution, intraperitoneal41), IGF1 (200 μg kg−1 body weight, intraperitoneal twice a day on the days of fasting); insulin (20 mU kg−1 body weight, intraperitoneal once a day on the days of fasting); leptin (1 mg kg−1 body weight, intraperitoneal once a day on the day of fasting). During the 48 h of fasting, mice were individually housed in a clean, new cage to reduce coprophagy and the intake of the residual chow. Body weight was measured immediately before, during and after fasting. Fasting cycles were repeated every seven days to allow for complete recovery of body weight before a new cycle. The size of the tumours was measured twice a week and tumour volume was calculated using the formula: tumour volume (in mm3) = (w2 × W) × π/6, where w and W are lengths of the minor side and major side (in mm), respectively. The maximum tumour volume that was permitted by our Institutional Animal Care and Use Committee (IACUC) was 1,500 mm3, and in none of the experiments were these limits exceeded. Tumour masses were isolated at the end of the last fasting cycle, weighed, divided into two parts, snap frozen in liquid nitrogen and stored at −80 °C. Ten slices of 50 μm per tumour sample were subsequently utilized for ChIP–seq, proteomics and RNA-seq analyses. Sample size estimation was performed using PS (power and sample size calculation) software (Vanderbilt University). By this approach, we estimated that the number of mice that were assigned to each treatment group would reach a power of 0.85. The type I error probability associated with our tests of the null hypothesis was 0.05. Mice were assigned to the different experimental groups in a random fashion. Operators were unblinded, as blinding during animal experiments was not possible because mice were subject to a specific diet supply and daily treatment.\n\nTo establish mammary intraductal cell line-derived xenograft (MIND-CDX) models, T47D cells were intraductally injected as previously described39,42. Specifically, 1 × 106 T47D cells were dissociated to single cells with 0.05% trypsin and injected intraductally into the abdominal/inguinal mammary glands (both sides) of 8-week-old female NSG mice (Jackson Laboratory) with a 34G needle. To ensure stable outgrowth, T47D MIND-CDX mice were supplemented with 17β-oestradiol (Sigma, E2758) via the drinking water at a concentration of 4 µg ml−1 starting 7 days prior to tumour inoculation via intraductal injection. E2 supplementation was maintained throughout the experiment. To establish TSAE1 allograft models, BALB/c mice (Jackson Laboratory) were intraductally injected with of 1 × 104 single cells in PBS as described above (one gland). The IDC186 MIND-PDX model was established from a pre-menopausal Caucasian breast cancer patient, confirmed positive for ERα (95%) and PR (95%) but negative for HER2 (Extended Data Fig. 6h). To generate the PDX model, 5 × 104 single cells in PBS were intraductally injected into one of the abdominal mammary glands of 8-week-old female NSG mice (Jackson Laboratory) and supplemented with 17β-oestradiol (Sigma, E2758) as described above.\n\nThe xenograft model cohorts were monitored three times per week and tumours were palpated and measured via calliper in two dimensions. Mice were enrolled into treatment groups when the largest tumour per animal measured 50 mm3 for T47D and IDC186 xenografts and 25 mm3 for TSAE1 allografts, respectively. Mice were randomly allocated into treatment groups and received the following treatments: (1) vehicle treatment (corn oil, daily, oral gavage); (2) TMX (45 mg kg−1 in corn oil, daily, oral gavage); (3) Dexa (4 mg kg−1, 3 times per week, intraperitoneal injection); or (4) TMX plus Dexa. Mice were treated for 28 consecutive days for the TSAE1 and IDC186, 56 days for T47D (with a 1-week treatment break between days 28 and 35), or until the cumulative mammary tumour burden reached a volume of 1,500 mm3 and thus the maximally permitted disease end point. At euthanasia, mammary glands and full female reproductive tracts were collected in formalin, stained against haematoxylin and eosin (H&E) according to routine procedures, and uteri were analysed for histopathological abnormalities. Tumour measurements and post-mortem analysis were performed in blinded fashion. H&E slides were reviewed by a trained pathologist (J.-Y.S.) in a blinded manner. Slides were digitally processed using a PANNORAMIC 1000 whole slide scanner (3DHISTECH) and captured with the Slidescore software (www.slidescore.com).\n\nClinical studies of FMD in patients undergoing endocrine therapy for HR+ breast cancer\n\nThe NCT05748704 trial was conducted at the IRCCS Ospedale Policlinico San Martino (Genoa), between December 2022 and February 2024 and was approved by the Comitato Etico Regione Liguria. This trial consists of a single-arm phase I/II clinical study of a FMD with solid tumours who are candidates to receive active medical or radiotherapy treatment (or with medical treatment or radiotherapy already ongoing). The nutritional intervention consists of a low-calorie diet lasting 5 days and aimed at providing between 800 and 1,000 kcal day−1 (tentatively 10% carbohydrates, 15% proteins and 75% lipids). Throughout the clinical study, patients have received dietary counselling for the intervals between FMD cycles, aiming at providing an appropriate intake of proteins, essential fatty acids, vitamins and minerals43 and have also been invited to perform light/ or moderate daily muscle training to enhance muscle anabolism44. Study primary outcomes were the effects of the FMD regimen on the circulating levels of factors with pro- or anti-oncogenic activity (including insulin, IGF1, IGFBP1, IGFBP3, leptin, adiponectin, IL-6, TNF and IL-1β), as well as the effect of FMD cycles on leukocyte subpopulations with a role in tumour growth control, such as regulatory T cells, myeloid-derived suppressor cells (MDSCs) as well as natural killer (NK) cells, and its stem cell pool (for example, haematopoietic stem cells, endothelial stem cells, mesenchymal stem cells). Additional information on this trial is available at https://clinicaltrials.gov/ct2/show/NCT05748704. Patient serum for subsequent ELISA assays of circulating growth factors and adipokines has been routinely collected before and after the first, sixth and twelfth FMD cycle. Informed consent was obtained from all patients participating in the clinical trial.\n\nThe DigesT study (ClinicalTrials.gov ID: NCT03454282) trial was conducted between July 2018 and December 2020 and in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. The study protocol was approved by the Institutional Review Board (IRB) and the Ethics Committee of Fondazione IRCCS Istituto Nazionale dei Tumori Milan (INT 157/17). All patients provided written informed consent before any study procedures, as well as for the use of clinical and biological data for research purpose. The FMD nutritional intervention consisted in a 5-day, plant-based, calorie-restricted (up to 600 kcal on day 1; up to 300 kcal on days 2, 3, 4 and 5), low-carbohydrate, low-protein, nutritional regimen, as previously published6. Enrolled patients initiated the FMD 12–15 days before surgery, and underwent blood sampling after at least 8 h complete fasting on the morning (08:30 to 10:00) of FMD initiation (pre-FMD), and on the morning of FMD completion (post-FMD). Tumour samples for RNA-seq analyses were obtained diagnostic core biopsies performed at baseline (Pre-) and from matched surgical specimens (Post-). The primary outcomes of the study were to measure the absolute and relative changes in population of peripheral blood mononuclear cells before and after the FMD. Additional information on this trial is available at https://clinicaltrials.gov/ct2/show/NCT03454282.\n\nChIP–seq\n\nSnap-frozen xenografted tumours were double fixed using 2 mM of disuccinimidyl glutarate diluted in solution A (50 mM Hepes, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) for 25 min followed by 1% formaldehyde for 20 min, at room temperature. Cells were then lysed and sonicated accordingly to the protocol previously described45, with the difference of have performed 15 cycles of 30 s on, 30 s off in the sonication step (BioRuptor Pico, Diagenode). Obtained nuclear lysates were incubated overnight with 50 μl of protein A coated Dynabeads magnetic beads (10008D, Invitrogen) conjugated with 5 μg of ERα (06-935, Millipore), H3K27ac (39133, Active Motif), GR (12041S, Cell Signaling), PR (8757S, Cell Signaling) or JUN (9165S, Cell Signaling) antibodies. The resulting immunoprecipitated DNA was submitted for library preparation using the KAPA library kit (KK8234, Roche) and subsequently paired-end sequenced on the Illumina NovaSeq 6000 system with read length of 51 bp. ChIP–seq analyses were performed using an in house pipeline publicly available at https://github.com/sebastian-gregoricchio/ChIP_Zwart (v.0.1.2) with default parameters. In brief, all samples were aligned to reference genome Hg38/GRCh38 using Burrows-Wheeler Aligner46 (BWA v.0.5.10). Reads were filtered based on mapping quality (MAPQ ≥ 20), and duplicate reads were marked with Picard MarkDuplicates (v.2.19.0). MACS2 (v.2.1.2) was used to perform peak calling over input ChIP–seq samples; only peaks with a q-value < 0.01 were retained. DeepTools47 (v.2.5.3) was used to calculate the fraction of reads in peaks (FRiP) and normalized ChIP–seq signal. For visualization purposes, Reads Per Genomic Content (RPGC) normalization (1× coverage) signal was averaged among the replicates per each condition using deeptools bigwigCompare. Genome browser snapshots were generated using the R v.4.0.3 environment and Rseb48 (v.0.3.1) (https://github.com/sebastian-gregoricchio/Rseb). Tornado plots were generated using deepTools (v.2.5.3). Differential peak analyses were performed using diffBind49 (v.3.0.15). Peaks were defined as differential when the |log 2 (fold change)| >1.5 and adjusted P value <0.05. Genomic location annotation of the peaks was performed using ChIPSeeker50 (v.1.26.2) defining the promoter region as −2 kb:transcription start site:+1 kb. Transcription factor binding enrichment from public available datasets—GIGGLE analyses51—were performed using the tool available at the of CistromeDB website (http://cistrome.org/db/).\n\nCell lines\n\nThe MCF7, T47D and HEK293T cell lines were purchased from the American Type Culture Collection (ATCC). TSAE1 cells were a gift from C. Isacke laboratory28. All cell lines were kept in DMEM, high glucose, pyruvate (Gibco) and supplemented with 10% fetal bovine serum (FBS, Capricorn Scientific) and 1% penicillin-streptomycin (5,000 U ml−1, Life Technologies). For ligand treatment, 4-hydroxytamoxifen (HY16950; MedChemExpress) and SR11302 (HY-15870; MedChemExpress) were reconstituted in DMSO, and used in the described concentrations and time points. All cell lines were cultured at 5% CO 2 at 37 °C, were subjected to regular Mycoplasma testing, and underwent authentication by short tandem repeat profiling (Eurofins Genomics).\n\nCRISPR–Cas9-mediated knockout cell line generation\n\nGR-targeting single-guide RNA (NR3C1; ATGACTACGCTCAACATGTT) and non-targeting (NT) control guide RNA (GTATTACTGATATTGGTGGG) were separately cloned into the lentiCRISPR v.2 vector52. Using H3K293T cells, the CRISPR vectors were co-transfected with third-generation viral vectors using polyethyleneimine (PEI, Polysciences). After lentivirus production, the medium was collected and added to the MCF7 cells. Two days after infection, cells were selected for 2 weeks with 2 μg ml−1 puromycin (Sigma Aldrich), and knockout efficiency was confirmed by western blot and immunofluorescence.\n\nImmunoblotting\n\nTotal protein lysates were obtained using Laemmli buffer complemented with 1× complete protease inhibitor cocktail (Roche) and 1× phenylmethylsulfonyl fluoride (PMSF). Forty micrograms of protein per sample was resolved in a NuPAGE 4–12% Bis-Tris gel (NP0335BOX, Invitrogen) in 1× NuPAGE MOPS SDS Running Buffer (NP00012, Invitrogen) and sequentially transferred to a 0.45-μm nitrocellulose membrane (Santa Cruz Biotechnology). Protein detection was performed using antibodies raised to detect GR (1:1,000, 12041S, Cell Signaling) and β-actin (1:10,000, MAB1501R, Merck Millipore). Odyssey CLx Imaging system (Li-Cor Biosciences) and ImageStudio Lite v.5.2.5 (LI-COR Biosciences) software were used to scan and visualize the proteins.\n\nImmunofluorescence\n\nCells were fixed with 2% paraformaldehyde (103999, Merck) for 10 min, washed twice with PBS and subsequently permeabilized with 0.5% Triton/PBS (Triton X-100, Sigma Aldrich). Following two PBS washing steps, cells were blocked for 1 h in 1% bovine serum albumin (BSA, A8022, Sigma/Merck)/PBS solution before incubation with antibody against GR (1:100, 12041S, Cell Signaling). After two additional PBS washes, cells were incubated with Alexa Fluor 488 goat anti-rabbit IgG (1:1,000, A-11008, ThermoFisher Scientific) and DAPI (ProLong Gold Antifade Mountant, P36930, ThermoFisher Scientific) and signal detected using laser confocal microscopy (SP5, Leica).\n\nImmunohistochemistry\n\nImmunohistochemistry of the formalin-fixed, paraffin-embedded (FFPE) tumour samples was performed on a BenchMark Ultra (Ki-67) or a Discovery Ultra (ERα, PR, GR) automated stainer (Ventana Medical Systems). In brief, paraffin sections were cut at 3 µm, heated at 75 °C for 28 min and deparaffinised in the instrument with EZ prep solution (Ventana Medical Systems). Heat-induced antigen retrieval was carried out using Cell Conditioning 1 (CC1, Ventana Medical Systems) for 32 min (Ki-67, ERα, PR) or 64 min (GR) at 95 °C. Ki-67 was detected using the clone 30-9 (Ready-to-Use, 32 min at 37 °C, Roche Diagnostics/Ventana), GR using the clone D6H2L (1/600 dilution, 1 h at 37 °C, 12041, Cell Signalling), ERα using the clone SP1 (Ready-to-Use, 32 min at room temperature, Roche Diagnostics/Ventana) and PR using the clone 1E2 (Ready-to-Use, 32 min at room temperature, Roche Diagnostics/Ventana). In order to reduce background signal for the PR staining, after primary antibody incubation slides were incubated with normal antibody diluent (Roche Diagnostics) for 24 min. Bound Ki-67 antibody was detected using the OptiView DAB Detection Kit (Ventana Medical Systems). GR and ERα bound antibody was visualized using Anti-Rabbit HQ (Ventana Medical systems) for 12 min at 37 °C followed by Anti-HQ HRP (Ventana Medical systems) for 12 min at 37 °C and the ChromoMap DAB detection kit (Ventana Medical Systems). PR bound antibody was detected using OmniMap anti-Rabbit HRP (Ventana Medical systems) for 12 min at room temperature. followed by ChromoMap DAB detection kit (Ventana Medical Systems). Slides were counterstained with Hematoxylin and Bluing Reagent (Ventana Medical Systems). A PANNORAMIC 1000 scanner from 3DHISTECH was used to scan the slides at a 40× magnification and uploaded to the Slidescore software (www.slidescore.com). Digitized slides were further processed using QuPath (v.0.6.0)53. The analysis protocol begins with tissue detection using a pixel classifier, which differentiates foreground from background (white) pixels. Next, manual annotation is performed with the brush tool to delineate and exclude stroma areas from the region of interest. To identify Ki-67-positive and negative cells, the native cell detection tool is used with the optical density sum option for image analysis. Default parameters are applied, with adjustments made only to the pixel size (0.25 µm), based on the slide resolution, and the target cell size (8 µm) for accurate cell identification. Finally, the scoring is calculated as the proportion of positive cells relative to the total number of detected cells, providing a quantitative assessment of Ki-67 expression. All quantifications were compared and approved by a trained pathologist (J.S.).\n\nRNA-seq analyses\n\nMCF7 xenograft tumour RNA was isolated by homogenizing the tissue sample in 1 ml of RLT buffer (79216, Qiagen) and 1% β-mercaptoethanol using the Qiagen TissueLyserII (85300, Qiagen) for 6 min with frequency setting 30 (1 s−1) in combination with 5-mm stainless steel beads (69989, Qiagen). The total RNA was isolated using the RNeasy Mini Kit (74106, Qiagen), including an on column Dnase digestion (79254, Qiagen), according to the manufacturer’s instructions (Rneasy Mini Handbook, Qiagen). Quality and quantity of the total RNA was assessed by the 2100 Bioanalyzer using a Nano chip (Agilent). Total RNA samples having RNA integrity number (RIN) >8 were subjected to library generation. Strand-specific libraries were generated using the TruSeq Stranded mRNA sample preparation kit (Illumina, RS-122-2101/2) according to the manufacturer’s instructions (Illumina, document 1000000040498 v.00). In brief, polyadenylated RNA from intact total RNA was purified using oligo-dT beads. Following purification the RNA was fragmented, random primed and reverse transcribed using SuperScript II Reverse Transcriptase (Invitrogen, 18064-014) with the addition of actinomycin D. Second strand synthesis was performed using polymerase I and RnaseH with replacement of dTTP for dUTP. The generated cDNA fragments were 3′ end adenylated and ligated to IDT xGen UDI(10 bp)-UMI(9 bp) paired-end sequencing adapters (Integrated DNA Technologies) and subsequently amplified by 12 cycles of PCR. The libraries were analysed on a 2100 Bioanalyzer using a 7500 chip (Agilent), diluted and pooled equimolar into a multiplex sequencing pool. The libraries were sequenced with 51 paired-end reads on a NovaSeq 6000 using a Reagent Kit v.1.5 (100cycles) (Illumina). After sequencing, data was aligned to the human reference genome Hg38/GRCh38 using HISAT254 (v.2.1.0) and the number of reads per gene were calculated using HTSeq count55 (v.0.5.3). Gene expression differences, between the conditions, were determined using DESeq256 (v.1.22.2) with |log 2 (fold change)| > 1 and adjusted P value <0.05 cut-offs. Differentially expressed genes were ranked by log 2 (fold change expression) and used for gene set enrichment analysis (GSEA) on the Hallmark gene set from msigdbr (v.7.5.1), a previously published GR-activity signature16 or a newly developed PR-activity signature17 (Extended Data Table 3), using clusterProfiler57 (v.3.18.1), (pvalueCutoff = 0.05, pAdjustMethod = “BH”). GSEA enrichment plots have been generated using the plot.gsea function from the Rseb package48 (v.0.3.2).\n\nTumour RNA was extracted from FFPE tumour specimens from patients with breast cancer using the MasterPure Complete DNA and RNA Purification Kit (Lucigen, LGC Biosearch Technologies) following the manufacturer’s instructions. RNA quality was evaluated using Agilent RNA 6000 Nano Kit (Agilent Technologies) on the Agilent 2100 Bioanalyzer (Agilent Technologies). RNA-seq libraries were prepared using TruSeq Stranded Total RNA Library Prep Gold (20020598, Illumina) according to the manufacturer’s protocol and sequenced using 50 bp paired-end sequencing mode on Illumina Novaseq 6000 platform (Illumina). Differential gene expression analysis comparing Post- versus Pre- samples was performed using negative binomial distribution and Benjamini–Hochberg false discovery rate (FDR) with the Bioconductor package DESeq2, applying Wald tests on normalized counts to obtain log 2 (fold change) and P values for each gene. To evaluate the activity of pathways of interest (GR-activity signature and PR-activity signature16,17 (Extended Data Table 3) and Hallmark gene sets) we performed GSEA using the Bioconductor package clusterProfiler. GSEA was performed on genes ranked by the absolute value of log 10 (P value) scaled by the sign of log 2 (fold change), tested against gene lists of interest. The enrichment score and NES were computed for each gene set, and nominal P values were estimated by permutation testing. Multiple testing correction was applied using the Benjamini–Hochberg procedure to obtain FDR q values. To estimate the activity of pathways of interest at a single sample level we performed GSVA. Differences in enrichment scores between Post- and Pre- samples were determined by the paired Wilcoxon test. To correlate the activity of GR-activity signature and Hallmark gene sets of interest, their GSVA enrichment scores were correlated through Spearman’s linear correlation. All analyses were performed with R studio software (v.2023.03).\n\nProteomics\n\nFor protein digestion, frozen tissues were lysed in boiling guanidine HCl (GuHCl) lysis buffer as previously described58. Protein concentration was determined with a Pierce Coomassie (Bradford) Protein Assay Kit (Thermo Scientific), according to the manufacturer’s instructions. After dilution to 2 M GuHCl, aliquots corresponding to at least 1.05 mg of protein were digested twice (4 h and overnight) with trypsin (Sigma Aldrich) at 37 °C, enzyme:substrate ratio 1:75. Digestion was quenched by the addition of formic acid (final concentration 5%), after which the peptides were desalted on a Sep-Pak C18 cartridge (Waters). From the eluates, aliquots were collected for proteome analysis, the remainder being reserved for phosphoproteome analysis (not included in this work). Samples were vacuum dried and stored at −80 °C until LC–MS/MS analysis.\n\nPrior to mass spectrometry analysis, the peptides were reconstituted in 2% formic acid. Peptide mixtures were analysed by nano LC–MS/MS on an Orbitrap Exploris 480 Mass Spectrometer equipped with an EASY-NLC 1200 system (Thermo Scientific). Samples were directly loaded onto the analytical column (ReproSil-Pur 120 C18-AQ, 2.4 μm, 75 μm × 500 mm, packed in house). Solvent A was 0.1% formic acid/water and solvent B was 0.1% formic acid/80% acetonitrile. Samples were eluted from the analytical column at a constant flow of 250 nl min−1. For single-run proteome a 90-min gradient was employed containing a 78-min linear increase from 6 to 30% solvent B, followed by a 10-min wash.\n\nRaw data were analysed by DIA-NN (v.1.8)59 without a spectral library and with ‘Deep learning’ option enabled. The Swissprot Human database (20,395 entries, release 2021_04) was added for the library-free search. The Quantification strategy was set to Robust LC (high accuracy) and MBR option was enabled. The other settings were kept at the default values. The protein groups report from DIA-NN was used for downstream analysis in Perseus (v.1.6.15.0)60. Values were log 2 -transformed, after which proteins were filtered for at least 100% valid values in at least one sample group. Missing values were replaced by imputation based on a normal distribution using a width of 0.3 and a minimal downshift of 2.4. Differentially expressed proteins were determined using a Student’s t-test (threshold: FDR: 5% and S0: 0.1).\n\nDifferentially protein levels were ranked by log 2 (fold change) × P value and used for GSEA analysis on Hallmarks from the community-contributed functional database from the web-based Gene Set Analysis Toolkit (WebGestalt61). GSEA enrichment plots were generated as previously described.\n\nELISA\n\nMouse whole blood was collected in Eppendorf tubes. It was allowed to coagulate for 2 h at room temperature, centrifuged for 20 min at 4,000 rpm, then aliquoted into PCR tubes and stored at −80 °C until subsequent use. Whole blood from patients was collected in Vacuette Serum Clot Tubes (BD), centrifuged 20 min at 2,100 rpm then aliquoted into small tubes and stored at −80 °C until use. ELISA assays to detect mouse serum levels of cortisone and progesterone were purchased from R&D System and ALPCO respectively while ELISA assays to detect human serum levels of cortisol and progesterone were purchased from R&D System and Enzo, respectively.\n\nFlow cytometry\n\nBreast cancer nodules were macrodissected from TSAE1-bearing mice and processed to generate single-cell suspensions using the Tumour Dissociation Kit (Miltenyi Biotec, 130-096-730) in conjunction with the gentleMACS Octo Dissociator, following the manufacturers’ protocols. The resulting cell suspensions were passed through a 100-µm cell strainer and subsequently washed with fluorescence-activated cell sorting buffer (PBS containing 5% FBS). To ensure the removal of red blood cells, samples were treated with an erythrocyte lysis solution. Following this, samples were pre-incubated with an anti-CD16/CD32 antibody (1:400, 553142, BD Bioscience) and then stained with antibodies specific for extracellular markers, adhering to standard staining protocols. After staining for surface markers, cells were labelled with a live/dead viability dye and subsequently fixed and permeabilized using a fixation/permeabilization solution (eBioscience, Invitrogen) for intracellular staining. All antibodies utilized for flow cytometry were titrated to account for lot-dependent variations, as described in Extended Data Fig. 7f. Immune cell populations were classified as follows: lymphoid cells (CD45+CD11b−), myeloid cells (CD45+CD11b+), neutrophils (CD45+CD11b+Ly6G+), non-classical monocytes (CD45+CD11b+Ly6G−Ly6C−) and dendritic cells (CD45+F4/80−CD11chiMHCIIhi) (for gating strategy used, see Supplementary Fig. 1). Sample acquisition was performed using a five-laser Aurora spectral flow cytometer (Cytek Biosciences), and data analysis was conducted using FlowJo v.10 software.\n\nStatistical analysis\n\nStatistical analyses were performed using GraphPad Prism software v.10.4.1 (GraphPad Software) or in R v.4.0.2 (R Core Team 2020, https://www.R-project.org). Paired t-test or one-way analysis of variance (ANOVA) was used to calculate changes in the majority of the analyses (unless otherwise stated) and only P values <0.05 were considered significant. Two-tailed Wilcoxon signed rank test was used to compare cortisol plasmatic concentration measured before FMD (Pre-FMD) and after FMD (Post-FMD). For the animal experiments, a linear mixed-effects model was utilized to assess whether the mass volume exhibits a statistically significant trend relative to the treatment over time. The model was constructed using the two-way ANOVA or mixed-effect model (in case of missing data) from GraphPad Prism software v.10.4.1. The fixed-effects model matrix was generated by the interaction of time (measured in days after injection) and treatment. The random-effects term was specified as the interaction between the treatment group and the blocking factor of the mouse ID. Subsequent pairwise post hoc multiple comparisons were conducted using the same software. Statistical significance was determined by P values less than 0.05. Linear mixed-effect model results are presented in the Supplementary Information.\n\nReporting summary\n\nFurther information on research design is available in the Nature Portfolio Reporting Summary linked to this article.",
      "url": "https://www.nature.com/articles/s41586-025-09869-0",
      "source": "Nature",
      "published": "2025-12-11",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant scientific advancement showing that fasting can boost the efficacy of breast cancer therapy via glucocorticoid activation, with both animal experiments and clinical trials providing detailed evidence. This finding has broad implications for improving treatment outcomes for many breast cancer patients, representing a meaningful positive impact on public health. The article is focused on a single, well-defined topic and provides substantial context and experimental detail.",
      "category": "Health",
      "personality_title": "Fasting improves breast cancer treatment by activating key hormones",
      "personality_presentation": "**Context** – Breast cancer is often treated with hormone therapies, especially for types that respond to estrogen. Researchers are looking for ways to make these treatments work better and with fewer side effects.\n\n**What happened** – Scientists conducted studies on mice and patients to see if fasting could help breast cancer therapies work more effectively. They found that fasting activates glucocorticoid hormones, which help improve the effects of hormone therapy against certain breast cancers. In mouse models, fasting or drugs that mimic fasting’s hormone effects slowed tumor growth. Clinical trials with patients showed that a low-calorie fasting diet changed hormone levels and immune cells in ways that support cancer treatment.\n\n**Impact** – This study shows that fasting or drugs that activate glucocorticoids can boost breast cancer treatment, especially for cancers that depend on estrogen signals. Using fasting or similar approaches might reduce harmful side effects of therapy and improve how well it works. This is important because breast cancer is common, and better treatments can help many patients live longer and healthier lives.\n\n**What's next step** – Researchers will continue clinical trials to test fasting diets and glucocorticoid-related drugs in larger groups of breast cancer patients. They will also explore exactly how these hormones improve treatment and how to safely include fasting in cancer care plans.\n\n**One-sentence takeaway** – Fasting helps breast cancer treatments work better by activating hormones that support therapy and reduce tumor growth.\n",
      "personality_title_fr": "Le jeûne améliore le traitement du cancer du sein en activant des hormones clés",
      "personality_presentation_fr": "**Contexte** – Le cancer du sein est souvent traité par des thérapies hormonales, surtout pour les types sensibles à l'œstrogène. Les chercheurs cherchent des moyens d'améliorer l'efficacité de ces traitements tout en réduisant leurs effets secondaires.\n\n**Ce qui s'est passé** – Des scientifiques ont mené des études sur des souris et des patients pour voir si le jeûne pouvait renforcer l'effet des traitements contre le cancer du sein. Ils ont découvert que le jeûne active des hormones appelées glucocorticoïdes, qui améliorent les effets de la thérapie hormonale sur certains cancers du sein. Chez les souris, le jeûne ou des médicaments qui imitent ses effets ralentissaient la croissance des tumeurs. Des essais cliniques ont montré qu'un régime de jeûne faible en calories modifiait les niveaux d'hormones et les cellules immunitaires de manière favorable au traitement.\n\n**Impact** – Cette étude montre que le jeûne ou des médicaments activant les glucocorticoïdes peuvent renforcer les traitements du cancer du sein, en particulier pour les cancers dépendants des signaux d'œstrogène. Utiliser le jeûne ou des méthodes similaires pourrait réduire les effets secondaires et améliorer l'efficacité du traitement. C’est important car le cancer du sein est fréquent et de meilleurs traitements peuvent aider beaucoup de patients à vivre plus longtemps et en meilleure santé.\n\n**Prochaine étape** – Les chercheurs poursuivront les essais cliniques pour tester les régimes de jeûne et les médicaments liés aux glucocorticoïdes chez un plus grand nombre de patients. Ils étudieront aussi comment ces hormones améliorent le traitement et comment intégrer le jeûne en toute sécurité dans les soins du cancer.\n\n**Message clé en une phrase** – Le jeûne aide les traitements du cancer du sein à mieux fonctionner en activant des hormones qui soutiennent la thérapie et ralentissent la croissance tumorale.\n",
      "personality_title_es": "El ayuno mejora el tratamiento del cáncer de mama activando hormonas clave",
      "personality_presentation_es": "**Contexto** – El cáncer de mama se trata a menudo con terapias hormonales, especialmente en tipos que responden al estrógeno. Los investigadores buscan formas de mejorar la efectividad de estos tratamientos y reducir efectos secundarios.\n\n**Qué pasó** – Científicos realizaron estudios en ratones y pacientes para ver si el ayuno podía ayudar a que las terapias contra el cáncer de mama funcionaran mejor. Descubrieron que el ayuno activa hormonas llamadas glucocorticoides, que mejoran los efectos de la terapia hormonal en ciertos cánceres de mama. En ratones, el ayuno o medicamentos que imitan sus efectos hormonales frenaron el crecimiento de tumores. Ensayos clínicos en pacientes mostraron que una dieta baja en calorías y de ayuno cambió los niveles hormonales y las células inmunes para apoyar el tratamiento.\n\n**Impacto** – Este estudio muestra que el ayuno o medicamentos que activan glucocorticoides pueden aumentar la eficacia del tratamiento del cáncer de mama, especialmente en cánceres que dependen de señales de estrógeno. Usar ayuno o métodos similares podría reducir efectos dañinos y mejorar el tratamiento. Esto es importante porque el cáncer de mama es común y mejores tratamientos pueden ayudar a muchos pacientes a vivir más y mejor.\n\n**Próximo paso** – Los investigadores continuarán con ensayos clínicos para probar dietas de ayuno y medicamentos relacionados con glucocorticoides en más pacientes con cáncer de mama. También explorarán cómo estas hormonas mejoran el tratamiento y cómo usar el ayuno de forma segura en la atención médica.\n\n**Frase resumen** – El ayuno ayuda a que los tratamientos contra el cáncer de mama funcionen mejor al activar hormonas que apoyan la terapia y frenan el crecimiento tumoral.\n",
      "image_url": "public/images/news_image_Fasting-boosts-breast-cancer-therapy-efficacy-via-.png",
      "image_prompt": "A detailed, warm painting of a serene laboratory scene featuring gentle, stylized nude female mice peacefully housed in ventilated cages with soft light filtering in, alongside symbolic glowing clusters representing breast cancer tumors visibly shrinking; nearby, a subtle depiction of a delicate hormonal molecule structure (glucocorticoid) radiates calming energy, illustrating the enhanced therapeutic effect of fasting on cancer treatment, all rendered in natural, soft earth tones and muted pastels."
    }
  ]
}